Amalgamated Bank Mersana Therapeutics, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

A detailed history of Amalgamated Bank transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 3,769 shares of MRSN stock, worth $8,367. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,769

Previous 3,769 -0.0%

Holding current value

$8,367

Previous $8,000 12.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$2.16 - $5.94 $17,273 - $47,502	-7,997 Reduced 67.97%	3,769 $17,000
Q4 2023 Feb 06, 2024	SELL	$1.11 - $2.34 $1,013 - $2,136	-913 Reduced 7.2%	11,766 $27,000
Q2 2023 Aug 11, 2023	BUY	$3.08 - $9.55 $10,127 - $31,400	3,288 Added 35.01%	12,679 $41,000
Q1 2023 May 02, 2023	SELL	$4.0 - $7.02 $9,700 - $17,023	-2,425 Reduced 20.52%	9,391 $39,000
Q4 2022 Feb 10, 2023	BUY	$5.65 - $7.86 $2,062 - $2,868	365 Added 3.19%	11,816 $69,000
Q3 2022 Nov 09, 2022	BUY	$4.63 - $8.0 $1,463 - $2,528	316 Added 2.84%	11,451 $77,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $5.0 $979 - $1,725	345 Added 3.2%	11,135 $51,000
Q1 2022 Jun 30, 2022	SELL	$3.74 - $6.63 $3,164 - $5,608	-846 Reduced 7.27%	10,790 $43,000
Q4 2021 Feb 15, 2022	SELL	$5.48 - $9.86 $1,172 - $2,110	-214 Reduced 1.81%	11,636 $72,000
Q3 2021 Oct 29, 2021	SELL	$8.56 - $14.47 $1,463 - $2,474	-171 Reduced 1.42%	11,850 $112,000
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $159,638 - $217,219	12,021 New	12,021 $163,000
Q1 2021 May 13, 2021	SELL	$15.31 - $26.52 $127,440 - $220,752	-8,324 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $140,176 - $229,659	8,324 New	8,324 $221,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Mersana Therapeutics, Inc. Transaction History